Failure by the GMC
But what of the General Medical Council and its firm rules against medical self promotion? Section 62 of the guidance on Professional Conduct and Discipline (the "Blue Book") places an unequivocal duty on practitioners not to acquiesce in the publication of material commending their particular and personal skills or attainments. Arranging for such publicity is worse; and trying to "attract patients" or to achieve "financial benefit" is worse still. The Blue Book highlights the exceptional danger to patients of ''raising illusory hopes of a cure."
As a medical outsider it seems to me that the newspaper articles reporting uncritically on (and quoting) Sharp constituted a frontal assault by him on each cardinal aspect of the GMC's cautions against self promotion. Not only did they breach the rules but they also occasioned the precise damage to patients that the rules were constructed to prevent and in the precise way that was anticipated by the council-by in effect advertising a "cure" to "people seeking medical attention [and] The public has a widespread belief that the GMC exists to protect it. Perhaps not everyone shares this view of the purposes of the council. But it is clear that without a professional medical standards inspectorate with powers and resources to investigate in advance of formal complaints being made the council cannot hope to offer the public the protection it is thought to provide.
I was told that the GMC had not taken on this role in the past, depending instead on existing NHS supervisory systems. Given the government's determination to commercialise medicine, the problem of supervising medical standards in the private sector must surely compel the introduction of a suitably resourced, nationally organised inspectorate. District health authorities, which currently license and inspect private hospitals and clinics, freely admit that they do not have the skills or resources to police them effectively.Not least the cost of employing medical and nursing supervisory officers to visit and check private hospitals and clinics is far greater than the licence fees hospitals must pay to be registered.
Private hospitals also acknowledge that they are lightly supervised and could easily mislead a district health authority. On this occasion a private hospital was misled by Dr Sharp. It now acknowledges that it was "questionable" whether it sufficiently checked his claims to have ethical or scientific approval for what he was doing.
But private hospitals are not required to have ethical or scientific committees to approve experiments or innovative treatments. In practice, many do not have such committees. In effect, these private hospitals operate as landlords and franchise operations to consultants, who rent their space and facilities. Although patients and the public will have obvious expectations about the standards of ethical medical care to be obtained in an institution using the name "hospital," mechanisms commensurate with those in the NHS to ensure that these standards are maintained do not exist. These matters need urgent legislation.
ANY QUESTIONS
Icing sugar contains up to 1 5% of aluminium sodium silicate. Would acid gastricjuice release the aluminium for absorption into the bloodstream, and ifso could any harm be caused?
Aluminium sodium silicate is added as an anticaking agent to some, but not all, icing sugars to ensure a smooth mix when the icing is prepared. It is an approved additive with an unlimited acceptable daily intake at present; it contains about 13% of aluminium so a typical iced cake could provide about 23 mg aluminium/100 g. The substance is virtually insoluble in water and solubilises only slowly in hot strong acid, so probably only a small amount of the aluminium is available for absorption into the body. In people with normal renal function the risks would almost certainly be small. -D A T SOUTHGATE, head, AFRC Institute ofFood Research, Norwich A woman had a boy who died in his first year of spinomuscular atrophy (Werdnig-Hoffman disease). What is the likelihood offuture children developing the disease and is there an antenatal screening testfor it?
The spinal muscular atrophies are clinically and genetically a heterogeneous group of disorders, but the acute progressive infantile form (proximal spinal muscular atrophy type I or Werdnig-Hoffman disease) is the most clear cut. The onset is from birth to 3 months or a little later, with severe hypotonia leading to death usually within one year and with a mean of seven months. The diagnosis of Werdnig-Hoffman disease rests on the clinical presentation, including the ages at onset and death, delayed nerve conduction, and finding muscle atrophy on biopsy.
Inheritance is through an autosomal recessive gene, the parents being unaffected carriers of the disease gene, and the affected children inheriting this gene from both parents. Such carriers have been estimated to have a frequency of one in 80 of the population. As with any autosomal recessive disease the carrier parents of an affected child will run a one in four risk that any further child will also be affected. Their unaffected children will have a two in three chance of being a carrier, like the parents. Whether the other autosomal recessive types of proximal spinal muscular atrophy, especially those of childhood onset, are due to allelic mutations of the same gene or to genes at distinct loci is still not clear. We do not even know on which chromosome the Werdnig-Hoffman gene lies.
There is no means of prenatal diagnosis. Many mothers notice reduced fetal movements when carrying an affected fetus, but this subjective impression is not reliable or a sufficiently early method for prenatal diagnosis. I am not aware that any study of objective measurement of fetal movements in at risk pregnancies, whether by ultrasonography or other methods, has been conducted. I hope that eventually deoxyribonucleic acid markers linked to the gene for Werdnig-Hoffman disease, and even the disease gene itself, will be detected. When this is achieved prenatal diagnosis and carrier detection will become possible and ultimately the gene product will be identified. 
